Inhibrx Biosciences, Inc. (INBX)
(Real Time Quote from BATS)
$13.33 USD
+0.42 (3.25%)
Updated Feb 5, 2025 03:44 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
INBX 13.33 +0.42(3.25%)
Will INBX be a Portfolio Killer in February?
Zacks Investment Research is releasing its prediction for INBX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INBX
Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates
BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates
INBX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for INBX
BlackRock, Inc. Increases Stake in Inhibrx Biosciences Inc.
Inhibrx Biosciences Inc (INBX) Gets a Hold from JMP Securities
Inhibrx Biosciences Reports Promising Trial Results for INBRX-109
Inhibrx announces preliminary ozekibart data, initiates new expansion cohort
Inhibrx announces preliminary ozekibart data, initiates new expansion cohort